
Design and optimization of aspartate N-acetyltransferase inhibitors for the potential treatment of Canavan disease
Keywords: ANAT; aspartate N-acetyltransferase; CD; Canavan disease; DCM; dichloromethane; DTNB; dithionitrobenzoate; EDCl; 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide; HEPES; 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid; IPTG; isopropyl-β-thiogalactoside